Advancing new drug therapies for unmet medical needs

Developing novel drug therapies for unmet medical needs 2018-02-05T09:26:29+00:00

Dimerix Limited is a clinical stage biotechnology company that is listed on the Australian Stock Exchange (ASX:DXB)

Our vision is to positively improve human health by creating safe and effective new treatments for patients with unmet medical needs

Recent news and media

ASX – New corporate presentation

Dimerix has a new corporate presentation that details some of the scientific and strategic activities for our lead program, DMX-200 for [...]

Quarterly Review – Q2 FY2018

Quarter highlights DMX-200 Phase 2a in Chronic Kidney Disease sub-group analysis was released in November showing compelling efficacy signals in the [...]

Results of Entitlement Offer

Dimerix Limited or the “Company” (ASX: DXB), a clinical stage biotechnology company today announces results from its 1 for 2 pro-rata [...]

Click here to view analyst coverage
Click here to view our corporate fact sheet
Click here to view our corporate presentation